Want to see GB:COG full AI Analyst Report?
COG Stock Chart & Stats
31.00 p
-0.24 p(-0.74%)
At close: 4:00 PM EDT
31.00 p
-0.24 p(-0.74%)
Day’s Range― - ―
52-Week Range26.60 p - 45.00 p
Previous CloseN/A
Volume4.45K
Average Volume (3M)33.11K
Market Cap
£15.11M
Enterprise Value15.04M
Total Cash (Recent Filing)£582.00K
Total Debt (Recent Filing)£239.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 05, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding54,037,327
10 Day Avg. Volume10,269
30 Day Avg. Volume33,106
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)£10.53M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high gross margins indicate that the company’s cognitive assessment software and related services retain substantial value after direct costs. This provides a foundation for future operating leverage if revenue expands or operating costs become better aligned with the business’s scale.
Improved Balance SheetLower absolute debt and a stronger equity base have materially improved financial resilience compared with 2023 and 2024. This reduces balance-sheet pressure and gives the company more flexibility to sustain operations while it works toward restoring profitability and self-funded growth.
Reduced Cash BurnThe sharp reduction in operating and free-cash-flow outflows shows meaningful progress in controlling cash consumption, even though the business remains cash-flow negative. If maintained, this improvement could extend financial runway and reduce the funding required to support ongoing operations.
Bears Say
Persistent LossesFour consecutive years of operating and net losses demonstrate that the current revenue base has not yet supported the company’s full cost structure. Persistent unprofitability limits internally generated capital, weakens shareholder returns, and leaves execution dependent on further operating improvement.
Revenue Volatility And DeclineRevenue remains well below the 2023 peak and has been volatile, indicating that demand and study-related activity have not yet developed into a consistently expanding base. This makes it harder to absorb fixed operating costs and creates uncertainty around the timing of a return to sustainable profitability.
Negative Free Cash FlowAlthough the cash deficit narrowed substantially, the company still does not generate enough cash to fund its activities organically. Continued negative free cash flow can constrain investment capacity and may require additional financing if operating improvements do not persist or revenue growth remains uneven.
Cambridge Cognition Holdings News
COG FAQ
What was Cambridge Cognition Holdings Plc’s price range in the past 12 months?
Cambridge Cognition Holdings Plc lowest share price was 26.60 p and its highest was 45.00 p in the past 12 months.
What is Cambridge Cognition Holdings Plc’s market cap?
Cambridge Cognition Holdings Plc’s market cap is £15.11M.
When is Cambridge Cognition Holdings Plc’s upcoming earnings report date?
Cambridge Cognition Holdings Plc’s upcoming earnings report date is May 05, 2027 which is in 204 days.
How were Cambridge Cognition Holdings Plc’s earnings last quarter?
Cambridge Cognition Holdings Plc released its earnings results on Sep 16, 2026. The company reported -0.016 p earnings per share for the quarter.
Is Cambridge Cognition Holdings Plc overvalued?
According to Wall Street analysts Cambridge Cognition Holdings Plc’s price is currently Overvalued.
Does Cambridge Cognition Holdings Plc pay dividends?
Cambridge Cognition Holdings Plc does not currently pay dividends.
What is Cambridge Cognition Holdings Plc’s EPS estimate?
Cambridge Cognition Holdings Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cambridge Cognition Holdings Plc have?
Cambridge Cognition Holdings Plc has 54,037,327 shares outstanding.
What happened to Cambridge Cognition Holdings Plc’s price movement after its last earnings report?
Cambridge Cognition Holdings Plc reported an EPS of -0.016 p in its last earnings report. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of Cambridge Cognition Holdings Plc?
Currently, no hedge funds are holding shares in GB:COG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.